Logo1 (06torrentlogo1)
Darifenacin Tablet, Extended Release
Product Images NDC 72162-2570
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 72162-2570). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Logo2 (07torrentlogo2)
Figure1 (Figure 1)
Figure 2a Study 1 (Figure2a Study1)
Figure 2b Study 2 (Figure2b Study2)
Figure 2c Study 3 (Figure2c Study3)
Label (Lbl721622570)
The text contains information about a medicine in the form of film-coated extended-release tablets containing Darifenacin. Each tablet contains 8.930 mg of Darifenacin hydrobromide equivalent to 7.5 mg of Darifenacin. It is recommended to store the tablets at temperatures between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The tablets should be swallowed whole without chewing, cutting, or crushing them. The medication is intended for adult use only and should be kept out of reach of children. The product is manufactured by Torrent Pharmaceuticals Ltd and relabeled by Bryant Ranch Prepack, Inc. It should be dispensed in a tight, light-resistant container with a child-resistant closure. The usual dosage information can be found in the package insert.*
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
